

5 December 2018

Company Announcements Office Australian Securities Exchange 20 Bridge Street SYDNEY NSW 2000

Dear Sir or Madam

APPENDIX 3B, APPENDIX 3Y AND CLEANSING NOTICE

Please find attached an Appendix 3B and an Appendix 3Y Change of Director's Interest Notice for Mike Melby, in respect to the issue of 1,000,000 fully paid ordinary shares pursuant to shareholder approval on 27 November 2018.

Please also find attached a Notice given pursuant to Section 708A(5) of the Corporations Act in respect of the issue.

Yours faithfully By Order of the Board

Kevin HartCompany Secretary
MyFiziq Limited

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

| 25 602 | 111 115 | | | | |
|--------|--|---------------------------------------|--|--|--|
| 33 002 | 111 113 | | | | |
| We (th | We (the entity) give ASX the following information. | | | | |
| | 1 - All issues st complete the relevant sections (attach | sheets if there is not enough space). | | | |
| 1 | *Class of *securities issued or to be issued | Issue of fully paid ordinary shares | | | |
| 2 | M 1 C+ '' 1 | | | | |
| 2 | Number of *securities issued or to be issued (if known) or maximum number which may be issued | 1,000,000 ordinary shares | | | |
| | | | | | |
| 3 | Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion) | | | | |
| | | | | | |

Name of entity

MyFiziq Limited

⁺ See chapter 19 for defined terms.

| 4 | Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? | Yes |
|----|---|---|
| | If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | |
| 5 | Issue price or consideration | Nil |
| | | |
| 6 | Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) | Issued pursuant to a Contract for Services with Director, Michael Melby and following shareholder approval at the Annual General Meeting on 27 November 2018 |
| | | |
| 6a | Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? | Yes |
| | If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i | |
| 6b | The date the security holder resolution under rule 7.1A was passed | 27 November 2018 |
| 6c | Number of *securities issued without security holder approval under rule 7.1 | Nil |
| 6d | Number of *securities issued with security holder approval under rule 7.1A | Nil |
| | | |

Appendix 3B Page 2 01/08/2012

⁺ See chapter 19 for defined terms.

| 6e | Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | Nil | |
|----|--|----------------------|---|
| | | | |
| 6f | Number of securities issued under an exception in rule 7.2 | N/a | |
| | | | |
| 6g | If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. | N/a | |
| | | | |
| 6h | If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/a | |
| | | | |
| 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements | Refer Annexure 1 | |
| | | | |
| 7 | Dates of entering *securities into uncertificated holdings or despatch of certificates | 5 December 2018 | |
| | | | |
| | | Number | †Closs |
| 8 | Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable) | Number 83,538,555 | +Class Ordinary fully paid shares (MYQ) of which 3,500,000 are subject to a 12 month trading restriction |

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the securities in section 2 if applicable)

| Number | +Class |
|------------|---|
| 15,000,000 | Class A Performance Shares |
| 15,000,000 | Class B Performance Shares |
| 500,000 | Options exercisable at \$0.25 and expiring on 31 December 2018 |
| 2,750,000 | Options exercisable at \$0.10 and expiring on 31 December 2020 |
| 1,750,000 | Options exercisable at \$0.10 and expiring on 31 December 2021 |
| 1,000,000 | Options exercisable at \$0.20 and expiring on 30 September 2020 |
| 1,500,000 | Options exercisable at the lesser of \$0.40 and 150% of the 14 day VWAP calculated up to the vesting date, expiring on 31 December 2018. |
| 500,000 | Options exercisable at the lesser of \$0.50 and 150% of the 14 day VWAP calculated up to the vesting date, expiring on 31 July 2019 |
| 500,000 | Options exercisable at the lesser of \$0.50 and 150% of the 14 day VWAP calculated up to the vesting date, expiring on 31 December 2019 |
| 1,500,000 | Options exercisable at the lesser of \$0.60 and 150% of the 14 day VWAP calculated up to the vesting date, expiring on 31 December 2019 |

Appendix 3B Page 4 01/08/2012

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the securities in section 2 if applicable)

| Number | +Class |
|-----------|---|
| 400,000 | Options exercisable at \$0.50 and expiring on 31 December 2022 |
| 400,000 | Options exercisable at \$0.50 and expiring on 31 December 2023 |
| 2,000,000 | Performance rights expiring on 03.03.19 |
| 6,000,000 | Performance rights expiring on 30.11.19 |
| 2,000,000 | Performance rights expiring on 03.03.20 |
| 1,750,000 | Performance rights expiring on 31.12.20 |
| 2,000,000 | Performance rights expiring on 03.03.21 |
| 2,000,000 | Performance rights expiring on 03.03.22 |
| 1,000,000 | Performance rights expiring on 31.12.19 |
| 5,000,000 | Performance rights expiring on 03.09.21 |
| 500,000 | Convertible notes issued on 18 April 2018 and expiring 31 December 2019 |
| 450,000 | Convertible notes issued on 30 August 2018 and expiring 31 December 2019 |
| 350,000 | Convertible notes issued on 27 September 2018 and expiring 31 December 2019 |

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

| N/a | | | |
|-----|--|--|--|
| | | | |
| | | | |
| | | | |

⁺ See chapter 19 for defined terms.

Part 2 - Bonus issue or pro rata issue

| 11 | Is security holder approval required? | N/a |
|----|--|-----|
| 12 | Is the issue renounceable or non-renounceable? | N/a |
| 13 | Ratio in which the ⁺ securities will be offered | N/a |
| 14 | ⁺ Class of ⁺ securities to which the offer relates | N/a |
| 15 | ⁺ Record date to determine entitlements | N/a |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | N/a |
| 17 | Policy for deciding entitlements in relation to fractions | N/a |
| 18 | Names of countries in which the entity has *security holders who will not be sent new issue documents | N/a |
| | Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. | |
| 19 | Closing date for receipt of acceptances or renunciations | N/a |
| 20 | Names of any underwriters | N/a |
| 21 | Amount of any underwriting fee or commission | N/a |
| 22 | Names of any brokers to the issue | N/a |
| 23 | Fee or commission payable to the broker to the issue | N/a |

Appendix 3B Page 6 01/08/2012

⁺ See chapter 19 for defined terms.

| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders | N/a |
|----|---|-----|
| 25 | If the issue is contingent on *security holders' approval, the date of the meeting | N/a |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled | N/a |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | N/a |
| 28 | Date rights trading will begin (if applicable) | N/a |
| 29 | Date rights trading will end (if applicable) | N/a |
| 30 | How do *security holders sell their entitlements <i>in full</i> through a broker? | N/a |
| 31 | How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | N/a |
| 32 | How do *security holders dispose of their entitlements (except by sale through a broker)? | N/a |
| 33 | ⁺ Despatch date | N/a |

⁺ See chapter 19 for defined terms.

Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities 34 Type of securities (tick one) Securities described in Part 1 (a) (b) All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents 35 If the *securities are *equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders If the *securities are *equity securities, a distribution schedule of the additional 36 *securities setting out the number of holders in the categories 1 - 1.0001.001 - 5.000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37 A copy of any trust deed for the additional *securities Entities that have ticked box 34(b) 38 N/a Number of securities for which ⁺quotation is sought 39 Class of +securities for which N/a quotation is sought

Appendix 3B Page 8 01/08/2012

⁺ See chapter 19 for defined terms.

| 40 | Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? | N/a | |
|-------|---|--------|--------------------|
| | If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | | |
| 41 | Reason for request for quotation now | N/a | |
| | Example: In the case of restricted securities, end of restriction period | | |
| | (if issued upon conversion of another security, clearly identify that other security) | | |
| | | | |
| | | Number | ⁺ Class |
| 42 | Number and *class of all *securities quoted on ASX (including the securities in clause 38) | N/a | |
| | | | |
| | | | |
| Ouota | tion agreement | | |

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

⁺ See chapter 19 for defined terms.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 †securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

== == == ==

Sign here: Date: 5 December 2018

Company secretary

Kevin Hart

Print name:

+ See chapter 19 for defined terms.

Appendix 3B Page 10 01/08/2012

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for *eligible entities

Introduced 01/08/12

Part 1

| Rule 7.1 – Issues exceeding 15% of capital | | | | |
|---|-----------------------------------|--|--|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | | | |
| Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue | 79,038,555 | | | |
| Add the following: | | | | |
| Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 | 3,500,000 issued 3 September 2018 | | | |
| Number of fully paid ordinary securities issued in that 12 month period with shareholder approval | 1,000,000 issued 5 December 2018 | | | |
| Number of partly paid ordinary securities that became fully paid in that 12 month period | Nil | | | |
| Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | | | | |
| Subtract the number of fully paid ordinary securities cancelled during that 12 month period | Nil | | | |
| "A" | 83,538,555 | | | |

⁺ See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A" | | |
|---|---|--|
| "B" | 0.15 | |
| | [Note: this value cannot be changed] | |
| Multiply "A" by 0.15 | 12,530,783 | |
| Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used | | |
| Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued: | | |
| Under an exception in rule 7.2 | | |
| Under rule 7.1A | | |
| With security holder approval under rule 7.1 or rule 7.4 | | |
| Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | | |
| "C" | | |
| Step 4: Subtract "C" from ["A" x "lplacement capacity under rule 7.1 | B"] to calculate remaining | |
| "A" x 0.15 | 12,530,783 | |
| Note: number must be same as shown in Step 2 | | |
| Subtract "C" | | |
| Note: number must be same as shown in Step 3 | | |
| Total ["A" x 0.15] – "C" | 12,530,783 | |
| | [Note: this is the remaining placement capacity under rule 7.1] | |

⁺ See chapter 19 for defined terms.

Appendix 3B Page 12 01/08/2012

Part 2

| Rule 7.1A – Additional placement capacity for eligible entities | | | |
|--|------------------------------------|--|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | | |
| "A" | 83,538,555 | | |
| Note: number must be same as shown in Step 1 of Part 1 | | | |
| Step 2: Calculate 10% of "A" | | | |
| "D" | 0.10 | | |
| | Note: this value cannot be changed | | |
| Multiply "A" by 0.10 | 8,353,855 | | |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used | | | |
| Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A | Nil | | |
| Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items | | | |
| "E" | Nil | | |

⁺ See chapter 19 for defined terms.

| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A | | |
|---|--|--|
| "A" x 0.10 | 8,353,855 | |
| Note: number must be same as shown in Step 2 | | |
| Subtract "E" | Nil | |
| Note: number must be same as shown in Step 3 | | |
| Total ["A" x 0.10] – "E" | 8,353,855 | |
| | Note: this is the remaining placement capacity under rule 7.1A | |

Appendix 3B Page 14 01/08/2012

⁺ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| Name of entity | MYFIZIQ LIMITED |
|----------------|-----------------|
| ABN | 85 602 111 115 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director | Michael Melby |
|---------------------|-----------------|
| Date of last notice | 27 October 2017 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest | Indirect |
|--|--|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | FitLab Fund Management, LLC in which Mr Melby holds 50% ownership and is the co-managing partner |
| Date of change | 5 December 2018 |
| No. of securities held prior to change | Nil |
| Class | Fully Paid Ordinary Shares |
| Number acquired | 1,000,000 |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Issued for nil consideration following shareholder approval on 27 November 2018 |
| No. of securities held after change | 1,000,000 fully paid ordinary shares |

01/01/2011 Appendix 3Y Page 1

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback I contract of Services with Mr Melby and following Shareholder approval at Annual General Meeting held on 27 November 2018

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract | |
|--|--|
| Nature of interest | |
| Name of registered holder | |
| (if issued securities) | |
| Date of change | |
| No. and class of securities to which | |
| interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 - +Closed period

| Were the interests in the securities or contracts detailed | No |
|--|-----|
| above traded during a +closed period where prior written | |
| clearance was required? | |
| If so, was prior written clearance provided to allow the | N/a |
| trade to proceed during this period? | |
| If prior written clearance was provided, on what date was | N/a |
| this provided? | |

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

5 December 2018



Company Announcements Office Australian Securities Exchange 20 Bridge Street SYDNEY NSW 2000

Dear Sir or Madam

SECONDARY TRADING NOTICE – NOTIFICATION PURSUANT TO PARAGRAPH 708A(5)(e) OF THE CORPORATIONS ACT 2001

This notice is given by MyFiziq Limited (ACN 602 111 115) (MYQ or the Company) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) ("the Act").

On 5 December 2018, the Company issued 1,000,000 fully paid ordinary shares (Securities) for nil consideration under a Contract for Services with Director, Michael Melby, following shareholder approval at the Company's Annual General Meeting on 27 November 2018.

The shares were issued without disclosure to investors under Part 6D.2 of the Act.

The Company gives notice under section 708A(5)(e) of the Act that:

- (a) as a disclosing entity, MYQ is subject to regular reporting and disclosure obligations;
- (b) as at the date of this notice, MYQ has complied with the provisions of Chapter 2M as they apply to MYQ and section 674 of the Act; and
- (c) as at the date of this notice, there is no information that is 'excluded information' within the meaning of section 708A(7) and 708A(8) of the Act which is required to be disclosed by MYQ under section 708A(6)(e) of the Act.

Yours faithfully By Order of the Board

Kevin HartCompany Secretary
MyFiziq Limited